CR20140289A - Derivados de quinolina como inhibidores de la enzima pde10a - Google Patents

Derivados de quinolina como inhibidores de la enzima pde10a

Info

Publication number
CR20140289A
CR20140289A CR20140289A CR20140289A CR20140289A CR 20140289 A CR20140289 A CR 20140289A CR 20140289 A CR20140289 A CR 20140289A CR 20140289 A CR20140289 A CR 20140289A CR 20140289 A CR20140289 A CR 20140289A
Authority
CR
Costa Rica
Prior art keywords
inhibitors
derivatives
quinoline
pde10a
enzyme
Prior art date
Application number
CR20140289A
Other languages
English (en)
Inventor
Jan Kehler
Jacob Nielsen
Ask Püschl
John Paul Kilburn
Morten Langgård
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48667762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140289(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of CR20140289A publication Critical patent/CR20140289A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona derivados de quinolina de fórmula I que son inhibidores de la enzima PDE10A y, como tales, son útiles para tratar trastornos psiquiátricos y eurodegenerativos. En especial, la invención proporciona compuestos que son alt
CR20140289A 2011-12-21 2014-06-17 Derivados de quinolina como inhibidores de la enzima pde10a CR20140289A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161578320P 2011-12-21 2011-12-21
DKPA201100990 2011-12-21

Publications (1)

Publication Number Publication Date
CR20140289A true CR20140289A (es) 2014-08-18

Family

ID=48667762

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140289A CR20140289A (es) 2011-12-21 2014-06-17 Derivados de quinolina como inhibidores de la enzima pde10a

Country Status (32)

Country Link
US (2) US9216986B1 (es)
EP (1) EP2794606A1 (es)
JP (1) JP6073918B2 (es)
KR (1) KR20140105574A (es)
CN (1) CN104114554A (es)
AP (1) AP2014007697A0 (es)
AR (1) AR089361A1 (es)
AU (1) AU2012356885B2 (es)
BR (1) BR112014015192A2 (es)
CA (1) CA2859702A1 (es)
CL (1) CL2014001643A1 (es)
CO (1) CO6990727A2 (es)
CR (1) CR20140289A (es)
DO (1) DOP2014000141A (es)
EA (1) EA028824B1 (es)
EC (1) ECSP14010000A (es)
GE (1) GEP201706657B (es)
HK (1) HK1202861A1 (es)
IL (1) IL233226A (es)
MA (1) MA35860B1 (es)
MD (1) MD20140070A2 (es)
MX (1) MX348792B (es)
MY (1) MY165216A (es)
PE (1) PE20141945A1 (es)
PH (1) PH12014501434A1 (es)
RU (1) RU2624440C2 (es)
SG (1) SG11201403339YA (es)
TN (1) TN2014000268A1 (es)
TW (1) TWI570124B (es)
UA (1) UA111871C2 (es)
WO (1) WO2013092974A1 (es)
ZA (1) ZA201404533B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR089361A1 (es) 2011-12-21 2014-08-20 Lundbeck & Co As H Derivados de quinolina como inhibidores de la enzima pde10a
US9670230B2 (en) 2012-11-29 2017-06-06 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
ES2331519T3 (es) 2003-06-30 2010-01-07 Nycomed Gmbh Derivados de pirrolo-dihidroisoquinolina como inhibidores de pde10.
NZ544591A (en) 2003-06-30 2009-07-31 Altana Pharma Ag Pyrrolodihydroisoquinolines as PDE10 inhibitors
CA2534432A1 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
EP1723134A2 (en) 2004-02-18 2006-11-22 Pfizer Products Incorporated Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
CA2568929A1 (en) 2004-06-07 2005-12-22 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
AU2005282721A1 (en) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
EP2565191B1 (en) * 2008-05-14 2014-10-08 Astellas Pharma Inc. 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
UA102693C2 (ru) 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
JP2011201873A (ja) * 2010-03-03 2011-10-13 Mitsubishi Tanabe Pharma Corp 三置換ピリミジン化合物及びそのｐｄｅ１０阻害薬としての使用
NZ603789A (en) * 2010-05-26 2015-03-27 Sunovion Pharmaceuticals Inc Heteroaryl compounds and methods of use thereof
AR089361A1 (es) 2011-12-21 2014-08-20 Lundbeck & Co As H Derivados de quinolina como inhibidores de la enzima pde10a

Also Published As

Publication number Publication date
TN2014000268A1 (en) 2015-09-30
UA111871C2 (uk) 2016-06-24
NZ626279A (en) 2015-07-31
WO2013092974A1 (en) 2013-06-27
DOP2014000141A (es) 2014-07-31
MX2014007409A (es) 2014-08-01
RU2014127984A (ru) 2016-02-10
PE20141945A1 (es) 2014-12-18
RU2624440C2 (ru) 2017-07-04
IL233226A0 (en) 2014-08-31
JP6073918B2 (ja) 2017-02-01
KR20140105574A (ko) 2014-09-01
US20160303120A1 (en) 2016-10-20
JP2015502970A (ja) 2015-01-29
GEP201706657B (en) 2017-04-25
CA2859702A1 (en) 2013-06-27
TW201339156A (zh) 2013-10-01
US9801878B2 (en) 2017-10-31
EP2794606A1 (en) 2014-10-29
CO6990727A2 (es) 2014-07-10
ECSP14010000A (es) 2015-12-31
CL2014001643A1 (es) 2014-11-21
AP2014007697A0 (en) 2014-06-30
AR089361A1 (es) 2014-08-20
PH12014501434B1 (en) 2014-09-22
BR112014015192A8 (pt) 2017-06-13
EA201491152A1 (ru) 2015-01-30
MX348792B (es) 2017-06-29
BR112014015192A2 (pt) 2017-06-13
PH12014501434A1 (en) 2014-09-22
CN104114554A (zh) 2014-10-22
AU2012356885B2 (en) 2016-09-08
MA35860B1 (fr) 2014-12-01
MD20140070A2 (ro) 2014-12-31
EA028824B1 (ru) 2018-01-31
AU2012356885A1 (en) 2014-07-10
ZA201404533B (en) 2015-12-23
IL233226A (en) 2017-11-30
SG11201403339YA (en) 2014-07-30
HK1202861A1 (en) 2015-10-09
TWI570124B (zh) 2017-02-11
MY165216A (en) 2018-03-09
US9216986B1 (en) 2015-12-22
US20150376186A1 (en) 2015-12-31

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
CU20130115A7 (es) Compuestos y composiciones como inhibidores de trk
MX355728B (es) Inhibidores de cinasas.
UY35249A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos
DOP2014000062A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
NI201400078A (es) Derivados de lactamas útiles como inhibidores mutantes de idh1
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
UY34472A (es) Derivados modificados de 4-fenil-piridina
GT201200171A (es) Derivados de fenilimidazol heteroaromáticos como inhibidores de enzima pde10a
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
IN2014DN10576A (es)
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
GT201200180A (es) Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a
MX340756B (es) Compuestos de quinazolina como inhibidores de serina/treonina quinasa.
EA201301130A1 (ru) Имидазопиридазины в качестве ингибиторов акт киназы
MX362939B (es) Derivados de (aza-)isoquinolinona.
MX2014013090A (es) Derivados de pirrolotriazinona.
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
EA201691177A1 (ru) Ингибиторы серин/треонинкиназ
CR20140528A (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de Bace1
CR20140367A (es) Inhibidores de iap
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
MX2015007608A (es) Metodos y composiciones para inhibir cnksr1.